Cargando…

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

BACKGROUND: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779784/
https://www.ncbi.nlm.nih.gov/pubmed/35091386
http://dx.doi.org/10.1016/j.jns.2022.120155
_version_ 1784637662345297920
author Dreyer-Alster, Sapir
Menascu, Shay
Mandel, Mathilda
Shirbint, Emanuel
Magalashvili, David
Dolev, Mark
Flechter, Shlomo
Givon, Uri
Guber, Diana
Stern, Yael
Miron, Shmuel
Polliack, Michael
Falb, Rina
Sonis, Polina
Gurevich, Michael
Achiron, Anat
author_facet Dreyer-Alster, Sapir
Menascu, Shay
Mandel, Mathilda
Shirbint, Emanuel
Magalashvili, David
Dolev, Mark
Flechter, Shlomo
Givon, Uri
Guber, Diana
Stern, Yael
Miron, Shmuel
Polliack, Michael
Falb, Rina
Sonis, Polina
Gurevich, Michael
Achiron, Anat
author_sort Dreyer-Alster, Sapir
collection PubMed
description BACKGROUND: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed. OBJECTIVE: Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients. METHODS: We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response. RESULTS: Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administration (IQR 54–84). The frequency of any adverse event was 54.5%, with the most common reported adverse events being fatigue, local pain at the injection site, fever and muscle or joint pain. Transient increase in MS symptoms was reported in 3.8% of patients, none of them requiring treatment. The rate of acute relapses treated with IV steroids was 3.3%. In a sub-group of 55 patients, 20 untreated and 35 treated with vaccination-safe disease-modifying treatments, SARS-CoV-2 IgG levels increased 21-fold (median ± SD 21.6 ± 53.05). CONCLUSIONS: The third dose of COVID-19-BNT162b2 vaccine proved safe for MS patients, with no increased risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments show significant increase in SARS-CoV-2 IgG levels following the third dose of vaccination.
format Online
Article
Text
id pubmed-8779784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-87797842022-01-24 COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose Dreyer-Alster, Sapir Menascu, Shay Mandel, Mathilda Shirbint, Emanuel Magalashvili, David Dolev, Mark Flechter, Shlomo Givon, Uri Guber, Diana Stern, Yael Miron, Shmuel Polliack, Michael Falb, Rina Sonis, Polina Gurevich, Michael Achiron, Anat J Neurol Sci Article BACKGROUND: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed. OBJECTIVE: Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients. METHODS: We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response. RESULTS: Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administration (IQR 54–84). The frequency of any adverse event was 54.5%, with the most common reported adverse events being fatigue, local pain at the injection site, fever and muscle or joint pain. Transient increase in MS symptoms was reported in 3.8% of patients, none of them requiring treatment. The rate of acute relapses treated with IV steroids was 3.3%. In a sub-group of 55 patients, 20 untreated and 35 treated with vaccination-safe disease-modifying treatments, SARS-CoV-2 IgG levels increased 21-fold (median ± SD 21.6 ± 53.05). CONCLUSIONS: The third dose of COVID-19-BNT162b2 vaccine proved safe for MS patients, with no increased risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments show significant increase in SARS-CoV-2 IgG levels following the third dose of vaccination. Elsevier B.V. 2022-03-15 2022-01-21 /pmc/articles/PMC8779784/ /pubmed/35091386 http://dx.doi.org/10.1016/j.jns.2022.120155 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Dreyer-Alster, Sapir
Menascu, Shay
Mandel, Mathilda
Shirbint, Emanuel
Magalashvili, David
Dolev, Mark
Flechter, Shlomo
Givon, Uri
Guber, Diana
Stern, Yael
Miron, Shmuel
Polliack, Michael
Falb, Rina
Sonis, Polina
Gurevich, Michael
Achiron, Anat
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title_full COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title_fullStr COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title_full_unstemmed COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title_short COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
title_sort covid-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779784/
https://www.ncbi.nlm.nih.gov/pubmed/35091386
http://dx.doi.org/10.1016/j.jns.2022.120155
work_keys_str_mv AT dreyeralstersapir covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT menascushay covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT mandelmathilda covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT shirbintemanuel covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT magalashvilidavid covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT dolevmark covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT flechtershlomo covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT givonuri covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT guberdiana covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT sternyael covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT mironshmuel covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT polliackmichael covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT falbrina covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT sonispolina covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT gurevichmichael covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose
AT achironanat covid19vaccinationinpatientswithmultiplesclerosissafetyandhumoralefficacyofthethirdboosterdose